User Tools

Site Tools


abaloparatide_for_osteoporosis

Abaloparatide for osteoporosis

Abaloparatide increases bone formation for treating established osteoporosis.

Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis 1). Have not yet been studied in the chronic glucocorticoid population 2).

Unclassified

Last update nov 30 2019

3: Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019 Oct;7(19):e14225. doi: 10.14814/phy2.14225. PubMed PMID: 31565870; PubMed Central PMCID: PMC6766518.

4: Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Maturitas. 2019 Nov;129:12-22. doi: 10.1016/j.maturitas.2019.08.003. Epub 2019 Aug 10. PubMed PMID: 31547908.

5: Cheng C, Wentworth K, Shoback DM. New Frontiers in Osteoporosis Therapy. Annu Rev Med. 2019 Sep 11. doi: 10.1146/annurev-med-052218-020620. [Epub ahead of print] PubMed PMID: 31509477.

6: Pazianas M. Bones, heart and the new anabolic agent romosozumab. Postgrad Med J. 2019 Oct;95(1128):521-523. doi: 10.1136/postgradmedj-2019-136699. Epub 2019 Aug 17. PubMed PMID: 31422376.

7: Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr Med Res Opin. 2019 Dec;35(12):2097-2102. doi: 10.1080/03007995.2019.1656955. Epub 2019 Sep 11. PubMed PMID: 31418585.

8: Leder BZ, Zapalowski C, Hu MY, Hattersley G, Lane NE, Singer AJ, Dore RK. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. J Bone Miner Res. 2019 Aug 14. doi: 10.1002/jbmr.3848. [Epub ahead of print] PubMed PMID: 31411768.

9: Ardura JA, Portal-Núñez S, Alonso V, Bravo B, Gortazar AR. Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide. Trends Endocrinol Metab. 2019 Oct;30(10):756-766. doi: 10.1016/j.tem.2019.07.014. Epub 2019 Aug 11. Review. PubMed PMID: 31409530.

10: Krohn K, Schwartz EN, Chung YS, Lewiecki EM. Dual-Energy X-Ray Absorptiometry Monitoring With Trabecular Bone Score: The 2019 ISCD Official Positions. J Clin Densitom. 2019 Jul 9. pii: S1094-6950(19)30152-0. doi: 10.1016/j.jocd.2019.07.006. [Epub ahead of print] Review. PubMed PMID: 31383412.

11: Romosozumab (Evenity) for postmenopausal osteoporosis. Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86. PubMed PMID: 31170119.

12: Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol. 2019 Aug;166:185-191. doi: 10.1016/j.bcp.2019.05.024. Epub 2019 May 25. Review. PubMed PMID: 31136739.

13: McGreevy JL, Kane MP, Busch RS, Bakst G, ElDeiry S. A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report. J Am Pharm Assoc (2003). 2019 Jul - Aug;59(4):593-597. doi: 10.1016/j.japh.2019.03.017. Epub 2019 May 14. PubMed PMID: 31101442.

14: Cosman F. The evolving role of anabolic therapy in the treatment of osteoporosis. Curr Opin Rheumatol. 2019 Jul;31(4):376-380. doi: 10.1097/BOR.0000000000000616. PubMed PMID: 31090588.

15: Ning Z, Tan B, Chen B, Lau DSA, Wong TM, Sun T, Peng S, Li Z, Lu WW. Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration. Macromol Biosci. 2019 Jun;19(6):e1900020. doi: 10.1002/mabi.201900020. Epub 2019 May 8. PubMed PMID: 31066995.

16: Sølling ASK, Harsløf T, Langdahl B. Current Status of Bone-Forming Therapies for the Management of Osteoporosis. Drugs Aging. 2019 Jul;36(7):625-638. doi: 10.1007/s40266-019-00675-8. Review. PubMed PMID: 31066015.

17: Tanaka S. Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Rev. 2019 Apr 29;4(4):158-164. doi: 10.1302/2058-5241.4.180018. eCollection 2019 Apr. Review. PubMed PMID: 31057953; PubMed Central PMCID: PMC6491949.

18: Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos Int. 2019 Aug;30(8):1607-1616. doi: 10.1007/s00198-019-04999-4. Epub 2019 May 3. PubMed PMID: 31053927; PubMed Central PMCID: PMC6663928.

19: Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis. Bone. 2019 Jul;124:148-157. doi: 10.1016/j.bone.2019.04.025. Epub 2019 Apr 30. PubMed PMID: 31051317.

20: Tan X, Wen F, Yang W, Xie JY, Ding LL, Mo YX. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). Menopause. 2019 Aug;26(8):929-939. doi: 10.1097/GME.0000000000001321. PubMed PMID: 31021904.

21: Yang L, Kang N, Yang JC, Su QJ, Liu YZ, Guan L, Liu T, Meng XL, Wang Y, Hai Y. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2640-2668. doi: 10.26355/eurrev_201903_17414. PubMed PMID: 30964193.

22: Fontalis A, Kenanidis E, Kotronias RA, Papachristou A, Anagnostis P, Potoupnis M, Tsiridis E. Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. Expert Opin Pharmacother. 2019 Jun;20(9):1123-1134. doi: 10.1080/14656566.2019.1594772. Epub 2019 Apr 8. Review. PubMed PMID: 30958709.

23: Costa S, Fairfield H, Reagan MR. Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents. Bone. 2019 Jun;123:211-223. doi: 10.1016/j.bone.2019.03.038. Epub 2019 Apr 4. PubMed PMID: 30954729; PubMed Central PMCID: PMC6559822.

24: Reginster J-, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019 Jul;30(7):1465-1473. doi: 10.1007/s00198-019-04947-2. Epub 2019 Apr 6. PubMed PMID: 30953114; PubMed Central PMCID: PMC6614166.

25: Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. J Clin Endocrinol Metab. 2019 May 1;104(5):1623-1630. doi: 10.1210/jc.2019-00192. PubMed PMID: 30907957.

26: Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2019 Jun;30(6):1187-1194. doi: 10.1007/s00198-019-04890-2. Epub 2019 Mar 21. PubMed PMID: 30899994; PubMed Central PMCID: PMC6546661.

27: Merlotti D, Falchetti A, Chiodini I, Gennari L. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019 May;20(7):805-811. doi: 10.1080/14656566.2019.1583208. Epub 2019 Mar 11. Review. PubMed PMID: 30856013.

28: Lanske B, Chandler H, Pierce A, Brown J, Ominsky M, Kostenuik P, Hattersley G. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. J Orthop Res. 2019 Apr;37(4):812-820. doi: 10.1002/jor.24254. Epub 2019 Mar 21. PubMed PMID: 30790359.

29: Simmons BF 3rd, Caprio AJ. Abaloparatide (Tymlos) for Osteoporosis. Am Fam Physician. 2019 Feb 15;99(4):260-261. PubMed PMID: 30763045.

30: Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019 Oct;49(2):184-196. doi: 10.1016/j.semarthrit.2019.01.006. Epub 2019 Jan 10. PubMed PMID: 30737062.

31: Hills JM, Khan I, Archer KR, Sivaganesan A, Daryoush J, Hong DY, Dahir KM, Devin CJ, Stephens B. Metabolic and Endocrine Disorders in Pseudarthrosis. Clin Spine Surg. 2019 Jun;32(5):E252-E257. doi: 10.1097/BSD.0000000000000788. PubMed PMID: 30730424.

32: McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019 Feb 5;14(1):15. doi: 10.1007/s11657-019-0564-7. PubMed PMID: 30719589; PubMed Central PMCID: PMC6373333.

33: Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019 Jan 26;393(10169):364-376. doi: 10.1016/S0140-6736(18)32112-3. Review. PubMed PMID: 30696576.

34: Sleeman A, Clements JN. Abaloparatide: A new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019 Jan 25;76(3):130-135. doi: 10.1093/ajhp/zxy022. Review. PubMed PMID: 30689744.

35: Yang Y, Lei H, Wang B. Effect of the PTHrP(1-34) analog abaloparatide on inducing chondrogenesis involves inhibition of intracellular reactive oxygen species production. Biochem Biophys Res Commun. 2019 Feb 19;509(4):960-965. doi: 10.1016/j.bbrc.2019.01.049. Epub 2019 Jan 14. PubMed PMID: 30654932.

36: Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int. 2019 Mar;30(3):667-673. doi: 10.1007/s00198-018-04819-1. Epub 2019 Jan 11. PubMed PMID: 30635696; PubMed Central PMCID: PMC6422956.

37: Anagnostis P, Gkekas NK, Potoupnis M, Kenanidis E, Tsiridis E, Goulis DG. New therapeutic targets for osteoporosis. Maturitas. 2019 Feb;120:1-6. doi: 10.1016/j.maturitas.2018.11.010. Epub 2018 Nov 16. Review. PubMed PMID: 30583758.

38: Ehrenmann J, Schöppe J, Klenk C, Rappas M, Kummer L, Doré AS, Plückthun A. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat Struct Mol Biol. 2018 Dec;25(12):1086-1092. doi: 10.1038/s41594-018-0151-4. Epub 2018 Nov 19. PubMed PMID: 30455434.

39: Qiu Y, Yang W, Wang Q, Yan S, Li B, Zhai X. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Arch Osteoporos. 2018 Nov 7;13(1):121. doi: 10.1007/s11657-018-0534-5. Review. PubMed PMID: 30406425.

40: Rachner TD, Hofbauer LC, Göbel A, Tsourdi E. Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. J Mol Endocrinol. 2019 Feb 1;62(2):R145-R154. doi: 10.1530/JME-18-0173. Review. PubMed PMID: 30389901.

41: Ricarte FR, Le Henaff C, Kolupaeva VG, Gardella TJ, Partridge NC. Parathyroid hormone(1-34) and its analogs differentially modulate osteoblastic Rankl expression via PKA/SIK2/SIK3 and PP1/PP2A-CRTC3 signaling. J Biol Chem. 2018 Dec 28;293(52):20200-20213. doi: 10.1074/jbc.RA118.004751. Epub 2018 Oct 30. PubMed PMID: 30377251; PubMed Central PMCID: PMC6311504.

42: Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone. 2019 Mar;120:137-140. doi: 10.1016/j.bone.2018.10.015. Epub 2018 Oct 22. PubMed PMID: 30359763.

43: Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 2019 Mar;120:148-155. doi: 10.1016/j.bone.2018.10.012. Epub 2018 Oct 19. PubMed PMID: 30343166.

44: Bernhardsson M, Aspenberg P. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models. Acta Orthop. 2018 Dec;89(6):674-677. doi: 10.1080/17453674.2018.1523771. Epub 2018 Oct 18. PubMed PMID: 30334479; PubMed Central PMCID: PMC6300720.

45: Langdahl BL, Andersen JD. Treatment of Osteoporosis: Unmet Needs and Emerging Solutions. J Bone Metab. 2018 Aug;25(3):133-140. doi: 10.11005/jbm.2018.25.3.133. Epub 2018 Aug 31. Review. PubMed PMID: 30237992; PubMed Central PMCID: PMC6135648.

46: Ramchand SK, Seeman E. Advances and Unmet Needs in the Therapeutics of Bone Fragility. Front Endocrinol (Lausanne). 2018 Sep 6;9:505. doi: 10.3389/fendo.2018.00505. eCollection 2018. Review. PubMed PMID: 30237785; PubMed Central PMCID: PMC6135909.

47: Tabacco G, Bilezikian JP. Osteoanabolic and dual action drugs. Br J Clin Pharmacol. 2019 Jun;85(6):1084-1094. doi: 10.1111/bcp.13766. Epub 2019 Apr 3. Review. PubMed PMID: 30218587; PubMed Central PMCID: PMC6533433.

48: Le QA, Hay JW, Becker R, Wang Y. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Ann Pharmacother. 2019 Feb;53(2):134-143. doi: 10.1177/1060028018798034. Epub 2018 Aug 30. PubMed PMID: 30160186; PubMed Central PMCID: PMC6311620.

49: Haas AV, LeBoff MS. Osteoanabolic Agents for Osteoporosis. J Endocr Soc. 2018 Jul 9;2(8):922-932. doi: 10.1210/js.2018-00118. eCollection 2018 Aug 1. Review. PubMed PMID: 30087947; PubMed Central PMCID: PMC6065487.

50: Reginster JY, Hattersley G, Williams GC, Hu MY, Fitzpatrick LA, Lewiecki EM. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. Calcif Tissue Int. 2018 Nov;103(5):540-545. doi: 10.1007/s00223-018-0450-0. Epub 2018 Jun 27. PubMed PMID: 29951742; PubMed Central PMCID: PMC6182596.

51: Pietrogrande L, Raimondo E. Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs Today (Barc). 2018 May;54(5):293-303. doi: 10.1358/dot.2018.54.5.2800621. Review. PubMed PMID: 29911694.

52: Wolverton D, Elliott DP. Evaluating the Evidence Behind Treating Osteoporosis in the Oldest Adults. Consult Pharm. 2018 Jun 1;33(6):308-316. doi: 10.4140/TCP.n.2018.308. Review. PubMed PMID: 29880092.

53: Choksi P, Jepsen KJ, Clines GA. The challenges of diagnosing osteoporosis and the limitations of currently available tools. Clin Diabetes Endocrinol. 2018 May 29;4:12. doi: 10.1186/s40842-018-0062-7. eCollection 2018. Review. PubMed PMID: 29862042; PubMed Central PMCID: PMC5975657.

54: Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957. doi: 10.1210/jc.2018-00163. PubMed PMID: 29800372; PubMed Central PMCID: PMC6097601.

55: Dede AD, Callan M. Treatment of osteoporosis: whom, how and for how long? Br J Hosp Med (Lond). 2018 May 2;79(5):259-264. doi: 10.12968/hmed.2018.79.5.259. Review. PubMed PMID: 29727238.

56: Makino A, Takagi H, Takahashi Y, Hase N, Sugiyama H, Yamana K, Kobayashi T. Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide. Calcif Tissue Int. 2018 Sep;103(3):289-297. doi: 10.1007/s00223-018-0422-4. Epub 2018 May 3. PubMed PMID: 29725706; PubMed Central PMCID: PMC6105163.

57: Khan AZ, Rames RD, Miller AN. Clinical Management of Osteoporotic Fractures. Curr Osteoporos Rep. 2018 Jun;16(3):299-311. doi: 10.1007/s11914-018-0443-y. Review. PubMed PMID: 29637519.

58: Gittoes N. Progress and Problems in Bone and Mineral Disorders. Eur Endocrinol. 2017 Apr;13(1):19-20. doi: 10.17925/EE.2017.13.01.19. Epub 2017 Apr 3. PubMed PMID: 29632601; PubMed Central PMCID: PMC5813440.

59: Liu Y, Levack AE, Marty E, Or O, Samuels BP, Redko M, Lane JM. Anabolic agents: what is beyond osteoporosis? Osteoporos Int. 2018 May;29(5):1009-1022. doi: 10.1007/s00198-018-4507-8. Epub 2018 Apr 7. Review. PubMed PMID: 29627891; PubMed Central PMCID: PMC5949085.

60: Cosman F. Long-term treatment strategies for postmenopausal osteoporosis. Curr Opin Rheumatol. 2018 Jul;30(4):420-426. doi: 10.1097/BOR.0000000000000509. Review. PubMed PMID: 29621030.

61: Laurent MR. Bone: best papers of the year 2017. Arch Osteoporos. 2018 Mar 15;13(1):29. doi: 10.1007/s11657-018-0437-5. Review. PubMed PMID: 29546647.

62: McClung MR, Harvey NC, Fitzpatrick LA, Miller PD, Hattersley G, Wang Y, Cosman F. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018 Jul;25(7):767-771. doi: 10.1097/GME.0000000000001080. PubMed PMID: 29462094; PubMed Central PMCID: PMC6015760.

63: McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD. Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. Calcif Tissue Int. 2018 Jun;102(6):634. doi: 10.1007/s00223-018-0390-8. PubMed PMID: 29383409; PubMed Central PMCID: PMC6828013.

64: Gennari L, Bilezikian JP. New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother. 2018 Feb;19(3):253-264. doi: 10.1080/14656566.2018.1428559. Epub 2018 Jan 19. Review. PubMed PMID: 29350069.

65: McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD. Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. Calcif Tissue Int. 2018 Jun;102(6):627-633. doi: 10.1007/s00223-017-0375-z. Epub 2017 Dec 28. Erratum in: Calcif Tissue Int. 2018 Jan 31;:. PubMed PMID: 29285549; PubMed Central PMCID: PMC5956009.

66: Fukumoto S. [Drugs for osteoporosis.]. Clin Calcium. 2018;28(1):114-116. doi: CliCa1801114116. Japanese. PubMed PMID: 29279435.

67: Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int. 2018 Mar;29(3):685-697. doi: 10.1007/s00198-017-4323-6. Epub 2017 Dec 19. PubMed PMID: 29260289; PubMed Central PMCID: PMC5834552.

68: Reginster JY, Al Daghri N, Kaufman JM, Bruyère O. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Expert Opin Pharmacother. 2018 Feb;19(2):159-161. doi: 10.1080/14656566.2017.1418857. Epub 2017 Dec 22. PubMed PMID: 29251010.

69: Boyce EG, Mai Y, Pham C. Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist. Ann Pharmacother. 2018 May;52(5):462-472. doi: 10.1177/1060028017748649. Epub 2017 Dec 14. Review. PubMed PMID: 29241341.

70: Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int. 2018 Feb;29(2):323-328. doi: 10.1007/s00198-017-4304-9. Epub 2017 Nov 22. PubMed PMID: 29167971; PubMed Central PMCID: PMC5818587.

71: Canalis E. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. Eur J Endocrinol. 2018 Feb;178(2):R33-R44. doi: 10.1530/EJE-17-0920. Epub 2017 Nov 7. Review. PubMed PMID: 29113980; PubMed Central PMCID: PMC5819362.

72: Tay D, Cremers S, Bilezikian JP. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br J Clin Pharmacol. 2018 Feb;84(2):252-267. doi: 10.1111/bcp.13455. Epub 2017 Dec 6. Review. PubMed PMID: 29049872; PubMed Central PMCID: PMC5777439.

73: Reginster JY, Al Daghri NM, Bruyere O. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opin Pharmacother. 2017 Dec;18(17):1811-1813. doi: 10.1080/14656566.2017.1395021. Epub 2017 Nov 14. PubMed PMID: 29048260.

74: Ansari N, Ho PW, Crimeen-Irwin B, Poulton IJ, Brunt AR, Forwood MR, Divieti Pajevic P, Gooi JH, Martin TJ, Sims NA. Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. J Bone Miner Res. 2018 Jan;33(1):137-153. doi: 10.1002/jbmr.3291. Epub 2017 Oct 3. PubMed PMID: 28914969.

75: Dede AD, Makras P, Anastasilakis AD. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. Expert Opin Investig Drugs. 2017 Oct;26(10):1137-1144. doi: 10.1080/13543784.2017.1371136. Epub 2017 Aug 29. Review. PubMed PMID: 28836858.

76: Minisola S, Cipriani C, Occhiuto M, Pepe J. New anabolic therapies for osteoporosis. Intern Emerg Med. 2017 Oct;12(7):915-921. doi: 10.1007/s11739-017-1719-4. Epub 2017 Aug 5. Review. PubMed PMID: 28780668.

77: Lovato C, Lewiecki EM. Emerging anabolic agents in the treatment of osteoporosis. Expert Opin Emerg Drugs. 2017 Sep;22(3):247-257. doi: 10.1080/14728214.2017.1362389. Epub 2017 Aug 4. Review. PubMed PMID: 28756709.

78: Uebelhart B, Ferrari S. [Osteoporosis]. Rev Med Suisse. 2017 Jan 11;13(544-545):88-90. Review. French. PubMed PMID: 28703545.

79: Tella SH, Kommalapati A, Correa R. Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300. Review. PubMed PMID: 28680788; PubMed Central PMCID: PMC5493470.

80: O'Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture. Clin Ther. 2017 Jul;39(7):1276-1290. doi: 10.1016/j.clinthera.2017.05.348. Epub 2017 Jun 17. PubMed PMID: 28629610.

81: Shirley M. Abaloparatide: First Global Approval. Drugs. 2017 Aug;77(12):1363-1368. doi: 10.1007/s40265-017-0780-7. PubMed PMID: 28624872.

82: Abaloparatide (Tymlos) for postmenopausal osteoporosis. Med Lett Drugs Ther. 2017 Jun 19;59(1523):97-98. PubMed PMID: 28609423.

83: Fukumoto S, Matsumoto T. Recent advances in the management of osteoporosis. F1000Res. 2017 May 5;6:625. doi: 10.12688/f1000research.10682.1. eCollection 2017. Review. PubMed PMID: 28529724; PubMed Central PMCID: PMC5428497.

84: McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA. The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. J Bone Miner Res. 2017 Aug;32(8):1625-1631. doi: 10.1002/jbmr.3163. Epub 2017 Jun 26. PubMed PMID: 28474780; PubMed Central PMCID: PMC5553106.

85: Hamdy RC. Osteoporosis, an Update. J Clin Densitom. 2017 Apr - Jun;20(2):131. doi: 10.1016/j.jocd.2017.04.001. PubMed PMID: 28449814.

86: Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol. 2017 Jun;86:356-365. doi: 10.1016/j.yrtph.2017.04.001. Epub 2017 Apr 4. PubMed PMID: 28389324.

87: Sugiyama T, Oda H. Osteoporosis Therapy: Bone Modeling during Growth and Aging. Front Endocrinol (Lausanne). 2017 Mar 9;8:46. doi: 10.3389/fendo.2017.00046. eCollection 2017. PubMed PMID: 28337176; PubMed Central PMCID: PMC5343005.

88: Leder BZ. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. Curr Osteoporos Rep. 2017 Apr;15(2):110-119. doi: 10.1007/s11914-017-0353-4. Review. PubMed PMID: 28303448; PubMed Central PMCID: PMC5477638.

89: de Villiers TJ. The quest for new drugs to prevent osteoporosis-related fractures. Climacteric. 2017 Apr;20(2):103-106. doi: 10.1080/13697137.2017.1289659. Epub 2017 Mar 3. Review. PubMed PMID: 28286990.

90: Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd J. Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. J Clin Densitom. 2017 Apr - Jun;20(2):134-152. doi: 10.1016/j.jocd.2017.01.001. Epub 2017 Feb 6. PubMed PMID: 28185765.

91: Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009. PubMed PMID: 28160873.

92: Chew CK, Clarke BL. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. Maturitas. 2017 Mar;97:53-60. doi: 10.1016/j.maturitas.2016.12.003. Epub 2016 Dec 15. Review. PubMed PMID: 28159062.

93: Tanaka S. [Development of osteoporosis drugs -the past, the present and the future-.]. Clin Calcium. 2017;27(1):137-141. doi: CliCa1701137141. Japanese. PubMed PMID: 28017957.

94: Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):106-109. Epub 2016 Oct 5. Review. PubMed PMID: 27920805; PubMed Central PMCID: PMC5119706.

95: Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone. 2017 Feb;95:143-150. doi: 10.1016/j.bone.2016.11.027. Epub 2016 Nov 25. PubMed PMID: 27894941.

96: Martin TJ, Seeman E. Abaloparatide Is an Anabolic, but Does It Spare Resorption? J Bone Miner Res. 2017 Jan;32(1):11-16. doi: 10.1002/jbmr.3042. Epub 2016 Dec 13. PubMed PMID: 27859635.

97: Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone. 2017 Apr;97:314-319. doi: 10.1016/j.bone.2016.11.004. Epub 2016 Nov 5. PubMed PMID: 27826127.

98: Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res. 2017 Jan;32(1):24-33. doi: 10.1002/jbmr.3003. Epub 2016 Oct 17. PubMed PMID: 27748532.

99: Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM. Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. J Bone Miner Res. 2017 Jan;32(1):17-23. doi: 10.1002/jbmr.2991. Epub 2016 Sep 28. PubMed PMID: 27612281.

100: Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442. PubMed PMID: 27533157.

101: Milat F, Ebeling PR. Osteoporosis treatment: a missed opportunity. Med J Aust. 2016 Aug 15;205(4):185-90. Review. PubMed PMID: 27510350.

102: Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats. Calcif Tissue Int. 2016 Nov;99(5):489-499. Epub 2016 Jul 9. PubMed PMID: 27395059; PubMed Central PMCID: PMC5055567.

103: Knauerhase A, Willenberg HS. [Novel anti-osteoporotic drugs on the horizon]. Z Rheumatol. 2016 Jun;75(5):466-70. doi: 10.1007/s00393-016-0102-6. Review. German. PubMed PMID: 27256100.

104: Yamauchi M. [The Importance of teriparatide in the treatment of osteoporosis]. Clin Calcium. 2016 Jun;26(6):905-13. doi: CliCa1606905913. Japanese. PubMed PMID: 27230847.

105: Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother. 2016 Jun;17(8):1141-52. doi: 10.1080/14656566.2016.1176147. Epub 2016 May 6. Review. PubMed PMID: 27055223.

106: Harsløf T, Langdahl BL. New horizons in osteoporosis therapies. Curr Opin Pharmacol. 2016 Jun;28:38-42. doi: 10.1016/j.coph.2016.02.012. Epub 2016 Mar 15. Review. PubMed PMID: 26989807.

107: Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2016 Jan;157(1):141-9. doi: 10.1210/en.2015-1726. Epub 2015 Nov 12. PubMed PMID: 26562265; PubMed Central PMCID: PMC4701881.

108: McClung MR. Emerging Therapies for Osteoporosis. Endocrinol Metab (Seoul). 2015 Dec;30(4):429-35. doi: 10.3803/EnM.2015.30.4.429. Epub 2015 Sep 10. Review. PubMed PMID: 26354487; PubMed Central PMCID: PMC4722395.

109: Makras P, Delaroudis S, Anastasilakis AD. Novel therapies for osteoporosis. Metabolism. 2015 Oct;64(10):1199-214. doi: 10.1016/j.metabol.2015.07.011. Epub 2015 Jul 21. Review. PubMed PMID: 26277199.

110: Ferrari S. Future directions for new medical entities in osteoporosis. Best Pract Res Clin Endocrinol Metab. 2014 Dec;28(6):859-70. doi: 10.1016/j.beem.2014.08.002. Epub 2014 Aug 20. Review. PubMed PMID: 25432357.

111: Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13. PubMed PMID: 25393645.

112: Polyzos SA, Makras P, Efstathiadou Z, Anastasilakis AD. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opin Investig Drugs. 2015 Feb;24(2):145-57. doi: 10.1517/13543784.2015.973021. Epub 2014 Oct 15. Review. PubMed PMID: 25316089.

113: Feurer E, Chapurlat R. Emerging drugs for osteoporosis. Expert Opin Emerg Drugs. 2014 Sep;19(3):385-95. doi: 10.1517/14728214.2014.936377. Epub 2014 Jul 4. Review. PubMed PMID: 24995794.

1)
Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz162. doi: 10.1210/clinem/dgz162. [Epub ahead of print] PubMed PMID: 31674644.
2)
Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019. PubMed PMID: 31692480; PubMed Central PMCID: PMC6711555.
abaloparatide_for_osteoporosis.txt · Last modified: 2019/11/30 13:17 by administrador